Zimmer Biomet Holdings, Inc. Overview
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is gearing up to announce its financial results for the third quarter of 2024. The report is expected to be released before the market opens, creating anticipation among investors and analysts alike.
Recent Performance Highlights for ZBH
In the most recent quarter, the company reported earnings of $2.01 per share, surpassing the consensus estimate by 1.5%. Zimmer Biomet has consistently outperformed expectations, beating earnings estimates in each of the last four quarters, with an average surprise of 2.84%.
Financial Estimates Ahead of Earnings
For the upcoming quarter, the consensus estimate projects revenues to reach approximately $1.81 billion, which reflects a 3.3% increase compared to the same quarter last year. Moreover, earnings are anticipated to be about $1.75 per share, marking a notable improvement of 6.1% from the previous year's numbers.
Revisions in Earnings Estimates
Interestingly, the consensus estimate for earnings has seen a slight decline of 1.1% in the past month, settling at $1.75 per share. This adjustment raises some questions, especially considering the company’s robust track record.
Key Factors Influencing Q3 Performance
The MedTech industry giant is expected to witness substantial growth driven by its successful business segments. The Hip division is likely to report significant progress, thanks to innovative products enhancing surgical procedures. A recent launch, the HAMMR surgical impactor, has already gained notable traction, and the impending acquisition of OrthoGrid Systems, Inc. will bolster their offerings in AI-powered surgical assistance.
Internationally, the company is set to debut a second generation of hip posterior robotics, which is expected to contribute positively to its revenue streams in the upcoming report.
In the Knees segment, while challenges impacted growth, a 5% year-over-year increase was recorded in the preceding quarter, and this momentum is expected to continue. With new ROSA knee systems anticipated in the pipeline, coupled with the TMINI system in partnership with THINK Surgical, Zimmer Biomet aims to solidify its position in the market.
Analyzing ZBH's Market Position
Despite the recent fluctuations in earnings estimates, the overall market sentiment remains cautiously optimistic. Zimmer Biomet currently holds a Zacks Rank #4, indicating a slightly negative outlook. The Earnings ESP, indicative of the potential to beat estimates, stands at -1.65%, suggesting challenges ahead.
Comparison with Peers
Investors might find it beneficial to look at peers in the medical field. For instance, Atea Pharmaceuticals (NASDAQ: AVIR), with an Earnings ESP of +13.13%, presents a positive outlook as it approaches its earnings report on November 13. Similarly, RadNet (NASDAQ: RDNT) boasts an impressive Earnings ESP of +20.00% and is expected to announce its results soon.
Also noteworthy is TransMedics Group (NASDAQ: TMDX), which has an Earnings ESP of +26.63% and is projected to report a year-over-year earnings surge of 333.3% in the upcoming quarter.
Outlook and Conclusion
Despite potential challenges surrounding the Earnings ESP and recent estimate revisions, Zimmer Biomet Holdings, Inc. has positioned itself strategically in the market. The upcoming earnings report will reveal how effectively the company has navigated recent uncertainties and whether it can continue to deliver strong financial outcomes moving forward.
Frequently Asked Questions
When will Zimmer Biomet announce its Q3 earnings?
Zimmer Biomet is set to announce its third-quarter earnings results on October 30, prior to the market opening.
What were Zimmer Biomet's earnings in the last quarter?
In the last reported quarter, Zimmer Biomet earned $2.01 per share, exceeding estimates by 1.5%.
What is the forecast for Zimmer Biomet's revenues?
The consensus estimate for Zimmer Biomet's revenues in Q3 is approximately $1.81 billion, indicating a potential 3.3% increase year-over-year.
What challenges is Zimmer Biomet facing?
The company has faced challenges in its Knees segment due to supply constraints, yet year-over-year growth was still observed.
How do Zimmer Biomet's peers compare in earnings forecasts?
Peers like Atea Pharmaceuticals, RadNet, and TransMedics Group all exhibit positive earnings estimates, with expectations of significant growth in their upcoming reports.
